media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

FDA Approves Revolution Medicines’ Oral RAS Inhibitor Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer

On October 19, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), an oral RAS inhibitor from Revolution Medicines, Inc., for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval is based on a randomized, open-label, multicenter trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Participants received once-daily oral daraxonrasib or standard chemotherapy. The trial showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. Daraxonrasib targets multiple forms of the RAS protein, a key driver of tumor growth in most pancreatic adenocarcinomas, and the approved indication does not impose a biomarker-based eligibility criterion. The approval offers a new treatment option for pancreatic cancer patients, who have historically faced limited treatment choices and poor outcomes. The most common side effects reported with daraxonrasib included ...
- Source: drugdu
- 59
- October 20, 2026
Hansoh Pharma Enters Strategic ADC Collaboration with Roche Worth Over US$15.5 Billion

On the evening of October 19, 2026, Hansoh Pharmaceutical Group (03692.HK) announced that its wholly-owned subsidiaries Shanghai Hansoh Biomedical Co., Ltd., Changzhou Hansoh Pharmaceutical Co., Ltd. and Hansoh Bio, LLC (collectively, Hansoh) entered into a strategic collaboration and license agreement on October 17 with F. Hoffmann-La Roche Ltd. This marks the two companies’ second partnership in the antibody-drug conjugate (ADC) field. The collaboration spans a broad portfolio of ADC programs, comprising two preclinical Hansoh ADC programs and multiple ADC programs based on Roche-proposed targets and powered by Hansoh’s proprietary ADC technology platform. Under the agreement, Hansoh will lead the early development of the programs up to completion of global Phase Ia clinical trials, while Roche will be responsible for further worldwide development excluding the Chinese Mainland, Hong Kong, Macau and Taiwan. Hansoh retains all rights to develop, register and commercialize the programs within Greater China. Under the agreement, Hansoh will ...
- Source: drugdu
- 43
- October 20, 2026
New cough medicine launched

Recently, the National Medical Products Administration approved the marketing of Zihua Wenfei Zhike Granules , a Class 1.1 innovative traditional Chinese medicine submitted by Guangzhou Yuekang Biopharmaceutical Co., Ltd., a subsidiary of Yuekang Pharmaceutical , for the treatment of cough due to wind-cold lingering in the lungs . Cough is a common symptom of respiratory diseases, and post-infectious cough is particularly troublesome due to its prolonged course. Zihua Wenfei Zhike Granules are specifically indicated for cough due to wind-cold lingering in the lungs, providing a new medication option for patients with this syndrome whose illness lasts 3 to 6 weeks. From the perspective of the formulation, the product prescription is derived from an empirical formula that has been clinically verified over a long period of time . It is composed of six medicinal materials: Aster tataricus, Tussilago farfara, Belamcanda chinensis, dried ginger, mango kernel, and Schizonepeta tenuifolia. These herbs complement ...
- Source: drugdu
- 36
- October 20, 2026
Shining on the top stage! The world’s first three-target agonist DR10624 MASLD/MASH Phase II results were selected for the latest breakthrough abstract of AASLD.

On October 19, 2026, Huadong Medicine Co., Ltd. (hereinafter referred to as “Huadong Medicine”) announced that the results of the Phase II clinical trial (“DR10624-202 Study”) of DR10624, a first-in-class long-acting trispecific agonist independently developed by its holding subsidiary Zhejiang Daer Biotechnology Co., Ltd. (hereinafter referred to as “Daer Biotechnology”) for the treatment of metabolic-associated fatty liver disease (MASLD)/metabolic steatohepatitis (MASH), have been successfully selected as the Late Breaking Abstract (LBA) of The Liver Meeting® (TLM) 2026 of the American Association for the Study of Liver Diseases (AASLD) and will be presented in the form of a Late Breaking Parallel Presentation. The principal investigator of this study, Associate Vice-President (Research) and Professor Mok Hing-yiu of Medicine at the Chinese University of Hong Kong, along with Professor Wong Wai-sun, Assistant Dean (Development) of the Faculty of Medicine and Head of the Department of Gastroenterology and Hepatology, will deliver a presentation on ...
- Source: drugdu
- 43
- October 20, 2026
The world’s first long-acting anti-RSV monoclonal antibody has been commercially launched

Recently, the domestically developed long-acting anti-respiratory syncytial virus (RSV) monoclonal antibody, ritvirabimab injection (trade name: Newdox), was launched in Jinwan District, Zhuhai. This is the world’s first long-acting anti-RSV monoclonal antibody with 9 months of protection data after a single injection, and it was independently developed and produced by Zhuhai TechnoMed Pharmaceutical Co., Ltd. RSV is one of the most common pathogens causing lower respiratory tract infections in infants and young children. The risk of infection increases significantly during the autumn and winter seasons. It is often associated with diseases such as severe pneumonia and bronchiolitis, and poses a particularly prominent threat to premature infants, low birth weight infants, and infants with congenital cardiopulmonary diseases. Source: https://mp.weixin.qq.com/s?__biz=MzIxMjYwMDI5Nw==&mid=2247717580&idx=3&sn=3f2a07c30d243e6b52fc0aeb2869baee&chksm=96e51b57c73949dc987f0a25e6a5421a12bfd06db7332796d4078d21b0d18e20c36f3d42b430&scene=126&sessionid=0#rd
- Source: drugdu
- 36
- October 20, 2026
Lunan Pharmaceutical’s Weikangda® Tegafur Capsules Receive Marketing Approval in Pakistan

Recently, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received a drug registration certificate for Tegafur Capsules (Viconda®) issued by the Food and Drug Administration of Pakistan (DRAP) , marking that the product has officially obtained market access in Pakistan and can be sold and commercialized there. Tegafur capsules are a compound preparation composed of tegafur, gimeracil, and oteracil potassium. They can inhibit tumor cell proliferation, induce tumor cell apoptosis, enhance the effect of chemotherapy, and reduce the side effects of chemotherapy. They are mainly used to treat patients with unresectable locally advanced or metastatic gastric cancer. During the product’s market approval process in Pakistan, the registration team strictly adhered to local regulations and scientifically and rationally prepared technical documentation, ensuring the product’s successful approval. This provided local gastric cancer patients with a more efficient and accessible treatment option, and laid a solid foundation for subsequent ...
- Source: drugdu
- 37
- October 20, 2026
Announcement Regarding Nimodipine Tablets Passing the Generic Drug Consistency Evaluation

Securities Daily News, October 19th – Xinhua PharmaceuticalThe company announced that it recently received the “Approval Notice for Supplemental Application for Drug” for Nimodipine tablets issued by the National Medical Products Administration. The product has passed the consistency evaluation of generic drug quality and efficacy. The specification is 30mg. This product is used as a continuation treatment after prior use of Nimodipine injection, and can prevent and treat ischemic neurological injury caused by cerebral vasospasm following aneurysmal subarachnoid hemorrhage. It belongs to Category A of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2025)”. Source: https://finance.eastmoney.com/a/202610193900147785.html
- Source: drugdu
- 34
- October 20, 2026
Rosuvastatin Ezetimibe Tablets (I) Receive Registration Approval

Shanghai Securities News (China Securities Network) – Peking University MedicineOn the evening of October 19th, the company announced that it had recently received a Drug Registration Certificate issued by the National Medical Products Administration. Its application for “Rosuvastatin Ezetimibe Tablets (I)” has been reviewed and found to meet the relevant requirements for drug registration, and has been approved for registration. It is understood that the drug is classified as a Class 4 chemical drug, and each tablet contains 10mg of rosuvastatin calcium (calculated as C22H28FN3O6S) and 10mg of ezetimibe. Data shows that rosuvastatin-ezetimibe tablets (I) are a compound preparation composed of rosuvastatin (an HMG-CoA reductase inhibitor) and ezetimibe (a cholesterol absorption inhibitor). Their mechanisms of action are complementary; by inhibiting cholesterol absorption and synthesis, they lower plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), while increasing high-density lipoprotein ...
- Source: drugdu
- 34
- October 20, 2026
北大医药：瑞舒伐他汀依折麦布片(Ⅰ)获注册批件

上证报中国证券网讯北大医药10月19日晚间公告，近日公司收到国家药品监督管理局核准签发的有关《药品注册证书》，其申报的“瑞舒伐他汀依折麦布片(I)” 经审查，符合药品注册的有关要求，批准注册并发给药品注册证书。据悉，该药品注册分类为化学药品4类，规格为每片含瑞舒伐他汀钙10mg(按C22H28FN3O6S计)与依折麦布10mg。资料显示，瑞舒伐他汀依折麦布片(Ⅰ)是由瑞舒伐他汀（HMG-CoA还原酶抑制剂）和依折麦布（胆固醇吸收抑制剂）组成的复方制剂，二者作用机制互补，通过抑制胆固醇的吸收和合成，降低血浆总胆固醇（T-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白B（ApoB）、甘油三酯（TG）和非高密度脂蛋白胆固醇（non-HDL-C）的水平，并能提高高密度脂蛋白胆固醇（HDL-C）水平。其主要用于高胆固醇血症、纯合子型家族性高胆固醇血症（HoFH）的治疗。北大医药表示，上述药物注册批件的获得，进一步丰富了公司现有产品布局，有利于提升公司在慢病领域产品市场的竞争力，对公司未来业绩提升有积极作用。 Source: https://finance.eastmoney.com/a/202610193900214984.html
- Source: drugdu
- 33
- October 20, 2026
Telix teams up with Ekalia (IBA-Framatome JV) to scale up astatine-211 production in the U.S., advancing targeted alpha therapy

On 19 October 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., Euronext) and Framatome, announced a collaboration to advance scalable U.S. production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy (TAT). The collaboration establishes a framework for a dedicated U.S. source of 211At, a scarce, next-generation alpha-emitting isotope whose broader adoption has been constrained by limited production capacity. Under the arrangement, the first IBA alpha-beam cyclotron will be installed and operated at Telix’s RLS Radiopharmacies site in Trevose, near Philadelphia, Pennsylvania. Leveraging Telix’s vertically integrated U.S. manufacturing and distribution platform, the framework provides for the parties to evaluate additional installations across RLS sites as demand for 211At develops. The alliance brings together IBA’s specialized alpha-beam cyclotron technology, Framatome’s nuclear and isotope-production expertise, and Telix’s U.S. radiopharmacy and last-mile infrastructure, clinical portfolio and radiopharmaceutical development capabilities. ...
- Source: drugdu
- 53
- October 19, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.